Petri

GALY Inc. is a biotechnology company founded in 2019 and based in the United States, specializing in the production of cotton through cellular agriculture. Utilizing proprietary biomaterial technology, GALY creates cotton yarns in a laboratory setting, eliminating the need for traditional farming methods. This innovative approach produces high-quality cotton at a lower cost and with a reduced environmental impact compared to conventional cotton production. By supplying the textile industry with sustainable raw materials, GALY aims to provide clothing brands with eco-friendly alternatives to natural fabrics.

Modern Synthesis is bringing life to new materials by working with bacteria to commercially develop a new class of biobased textiles which offer: (1) Performance without plastics or harsh chemicals: Materials which achieve strength and durability without petrochemical binders, harmful chemistries or toxic byproducts. (2) Aesthetics without animals: A versatile process that unlocks a wide range of looks, feels, and functions to meet designers’ seasonal needs with zero animal inputs. (3) Scale without starting from scratch: A process that leverages abundant raw materials and is designed to integrate with existing manufacturing infrastructure. Modern Synthesis’ technology leverages the intrinsic versatility of bacterial nanocellulose, which is nature’s finest and strongest form of cellulose. Their process not only displaces animal leathers, plastic-based synthetics and other nonwoven textiles, but also generate entirely new possibilities for designers.

Minus is a beanless coffee company which produces coffee.

New Equilibrium Biosciences is focused on developing therapeutic drugs aimed at treating cancer and neurodegenerative diseases. The company employs a unique approach that integrates artificial intelligence with quantum chemistry to enhance biophysical experiments. This innovative platform specializes in the research and development of therapeutics that target intrinsically disordered proteins (IDPs), which are often implicated in various neurodegenerative disorders. By utilizing IDP-specific compound libraries, New Equilibrium Biosciences seeks to identify and exploit transient binding pockets on these proteins, facilitating the discovery of lead drug candidates. This approach aims to improve medical procedures and ultimately contribute to advancements in healthcare.

Yard Stick specializes in measuring soil carbon to support climate-friendly agricultural practices. By addressing significant measurement challenges, the company has developed an innovative handheld device that evaluates carbon stocks and changes in real-time using VisNIR spectrometry. This technology allows for accurate detection of organic carbon levels, significantly reducing the cost of soil carbon measurement by over 90%. As a result, Yard Stick aims to enhance the adoption of evidence-based regenerative practices, which can improve soil health, increase farmers' income, and contribute to combating climate change. Through its advancements, Yard Stick seeks to create opportunities for both scientists and farmers to effectively manage soil carbon, thus facilitating a more sustainable agricultural future.

Medsix is a medical technology company focused on enhancing patient outcomes through innovative wound drainage solutions. The company has developed a disposable sensor that can be attached to any wound drain, automating the monitoring of drain output with predictive analytics. This technology addresses the challenges associated with current manual monitoring practices, which often lead to inaccuracies in data collection and delayed detection of complications such as infections or blockages. By providing real-time insights, Medsix's sensor aims to facilitate earlier removal of drains, reduce recovery time, and improve overall clinical workflows for healthcare providers. Additionally, the solution is designed to benefit payers by decreasing hospital lengths of stay and readmission rates, ultimately enhancing reimbursement opportunities.

GALY Inc. is a biotechnology company founded in 2019 and based in the United States, specializing in the production of cotton through cellular agriculture. Utilizing proprietary biomaterial technology, GALY creates cotton yarns in a laboratory setting, eliminating the need for traditional farming methods. This innovative approach produces high-quality cotton at a lower cost and with a reduced environmental impact compared to conventional cotton production. By supplying the textile industry with sustainable raw materials, GALY aims to provide clothing brands with eco-friendly alternatives to natural fabrics.

Matterworks is a biotech startup that combines metabolomics with AI to simulate the metabolic environment. The startup is enabling real-time insights into cellular biology to accelerate therapeutic research, development, and manufacturing with an AI-driven cloud platform for metabolomics. Matterworks was founded by Mimoun Cadosch Delmar and Jack Geremia in 2019.

New Equilibrium Biosciences is focused on developing therapeutic drugs aimed at treating cancer and neurodegenerative diseases. The company employs a unique approach that integrates artificial intelligence with quantum chemistry to enhance biophysical experiments. This innovative platform specializes in the research and development of therapeutics that target intrinsically disordered proteins (IDPs), which are often implicated in various neurodegenerative disorders. By utilizing IDP-specific compound libraries, New Equilibrium Biosciences seeks to identify and exploit transient binding pockets on these proteins, facilitating the discovery of lead drug candidates. This approach aims to improve medical procedures and ultimately contribute to advancements in healthcare.